399 related articles for article (PubMed ID: 33755981)
1. Low prevalence of SARS-CoV-2 infection in inflammatory bowel disease.
Scucchi L; Neri B; Sarmati L; Mossa M; Sena G; Massoud R; Petruzziello C; Musumeci M; Marafini I; Calabrese E; Lolli E; Bernardini S; Andreoni M; Monteleone G; Biancone L
Eur Rev Med Pharmacol Sci; 2021 Mar; 25(5):2418-2424. PubMed ID: 33755981
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 Igg seroprevalence in IBD patients treated with biologics: first vs. second pandemic wave in a prospective study.
Mossa M; Neri B; Montesano L; Salvatori S; Marafini I; Scucchi L; Lolli E; Massoud R; Petruzziello C; Bernardini S; Calabrese E; Monteleone G; Biancone L
Eur Rev Med Pharmacol Sci; 2022 May; 26(10):3787-3796. PubMed ID: 35647861
[TBL] [Abstract][Full Text] [Related]
3. High seroprevalence against SARS-CoV-2 in non-vaccinated patients with inflammatory bowel disease from Northern India.
Kante B; Vuyyuru SK; Gupta R; Dwivedi T; Kumar P; Mundhra S; Golla R; Virmani S; Verma M; Makharia G; Ahuja V; Kedia S
Indian J Gastroenterol; 2023 Feb; 42(1):70-78. PubMed ID: 36738383
[TBL] [Abstract][Full Text] [Related]
4. A Seroprevalence Study of Anti-SARS-CoV-2 Antibodies in Patients with Inflammatory Bowel Disease during the Second Wave of the COVID-19 Pandemic in Italy.
Di Ruscio M; Lunardi G; Buonfrate D; Gobbi F; Bertoli G; Piccoli D; Conti A; Geccherle A; Variola A
Medicina (Kaunas); 2021 Oct; 57(10):. PubMed ID: 34684085
[No Abstract] [Full Text] [Related]
5. Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs.
Bossa F; Carparelli S; Latiano A; Palmieri O; Tavano F; Panza A; Pastore M; Marseglia A; D'Altilia M; Latiano T; Corritore G; Martino G; Nardella M; Guerra M; Terracciano F; Sacco M; Perri F; Andriulli A
Dig Liver Dis; 2021 Mar; 53(3):277-282. PubMed ID: 33423942
[TBL] [Abstract][Full Text] [Related]
6. Effect of anti-SARS-CoV-2 BNT162b2 mRNA vaccination on thrombin generation in children with inflammatory bowel disease.
Stercel V; Lóczi L; Kadenczki O; Nemes É; Nagy B; Hodossy-Takács R; Szabó AÁ; Fagyas M; Kappelmayer J; Szabó T; Bagoly Z
Front Immunol; 2023; 14():1257072. PubMed ID: 37965328
[TBL] [Abstract][Full Text] [Related]
7. Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study.
Bezzio C; Armuzzi A; Furfaro F; Ardizzone S; Milla M; Carparelli S; Orlando A; Caprioli FA; Castiglione F; Viganò C; Ribaldone DG; Zingone F; Monterubbianesi R; Imperatore N; Festa S; Daperno M; Scucchi L; Ferronato A; Pastorelli L; Balestrieri P; Ricci C; Cappello M; Felice C; Fiorino G; Saibeni S;
Aliment Pharmacol Ther; 2021 Dec; 54(11-12):1432-1441. PubMed ID: 34694009
[TBL] [Abstract][Full Text] [Related]
8. Seroprevalence of SARS-CoV2 in IBD Patients Treated with Biologic Therapy.
Berte' R; Mazza S; Stefanucci MR; Noviello D; Costa S; Ciafardini C; Mileti E; Mapelli M; Pasqualato S; Pinto S; Favale A; Vecchi M; Neurath MF; Atreya R; Fantini MC; Facciotti F; Caprioli F
J Crohns Colitis; 2021 May; 15(5):864-868. PubMed ID: 33211810
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 in IBD: The experience of a single tertiary IBD center.
Rizzello F; Calabrese C; Salice M; Calandrini L; Privitera H; Melotti L; Peruzzi G; Dussias N; Belluzzi A; Scaioli E; Decorato A; Siniscalchi A; Filippone E; Laureti S; Rottoli M; Poggioli G; Gionchetti P
Dig Liver Dis; 2021 Mar; 53(3):271-276. PubMed ID: 33451910
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory bowel disease is associated with higher seroprevalence rates of antibodies against SARS-CoV-2.
Łodyga M; Maciejewska K; Eder P; Waszak K; Stawczyk-Eder K; Michalak M; Dobrowolska A; Wiśniewska-Jarosińska M; Gąsiorowska A; Cicha M; Wierzba W; Rydzewska G
Pol Arch Intern Med; 2021 Mar; 131(3):226-232. PubMed ID: 33544564
[TBL] [Abstract][Full Text] [Related]
11. Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19.
Macaluso FS; Giuliano A; Fries W; Viola A; Abbruzzese A; Cappello M; Giuffrida E; Carrozza L; Privitera AC; Magnano A; Ferracane C; Scalisi G; Minissale MG; Giangreco E; Garufi S; Bertolami C; Cucinotta U; Graziano F; Casà A; Renna S; Teresi G; Rizzuto G; Mannino M; Maida M; Orlando A
Inflamm Bowel Dis; 2023 Feb; 29(2):217-221. PubMed ID: 35385102
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases.
Burke KE; Kochar B; Allegretti JR; Winter RW; Lochhead P; Khalili H; Colizzo FP; Hamilton MJ; Chan WW; Ananthakrishnan AN
Inflamm Bowel Dis; 2021 Jan; 27(2):155-161. PubMed ID: 33089863
[TBL] [Abstract][Full Text] [Related]
13. Seroprevalence of ANTI-SARS-CoV-2 antibodies in patients with inflammatory bowel disease.
Martin-Arranz MD; García-Ramírez L; Hernandez-Perez M; Montero Vega D; Martín-Arranz E; Sánchez-Azofra M; Poza Cordon J; Rueda Garcia JL; Noci Belda J; Verges Martínez-Meco T; Blanco San Miguel P; Suarez Ferrer C
Sci Rep; 2023 Apr; 13(1):7044. PubMed ID: 37120662
[TBL] [Abstract][Full Text] [Related]
14. A four-decade analysis of the incidence trends, sociodemographic and clinical characteristics of inflammatory bowel disease patients at single tertiary centre, Kuala Lumpur, Malaysia.
Mokhtar NM; Nawawi KNM; Verasingam J; Zhiqin W; Sagap I; Azman ZAM; Mazlan L; Hamid HA; Yaacob NY; Rose IM; Den ELN; Wan MS; Raja Ali RA
BMC Public Health; 2019 Jun; 19(Suppl 4):550. PubMed ID: 31196184
[TBL] [Abstract][Full Text] [Related]
15. Patients with inflammatory bowel disease on immunosuppressive drugs: perspectives' on COVID-19 and health care service during the pandemic.
Moum KM; Moum B; Opheim R
Scand J Gastroenterol; 2021 May; 56(5):545-551. PubMed ID: 33771086
[TBL] [Abstract][Full Text] [Related]
16. Serological response to vaccination against coronavirus disease-19 in patients with inflammatory bowel disease.
Mathur A; Sahu S; Rai S; Ghoshal U; Ghoshal UC
Indian J Gastroenterol; 2023 Feb; 42(1):64-69. PubMed ID: 36598745
[TBL] [Abstract][Full Text] [Related]
17. Intestinal Receptor of SARS-CoV-2 in Inflamed IBD Tissue Seems Downregulated by HNF4A in Ileum and Upregulated by Interferon Regulating Factors in Colon.
Verstockt B; Verstockt S; Abdu Rahiman S; Ke BJ; Arnauts K; Cleynen I; Sabino J; Ferrante M; Matteoli G; Vermeire S
J Crohns Colitis; 2021 Mar; 15(3):485-498. PubMed ID: 32915959
[TBL] [Abstract][Full Text] [Related]
18. Benign Evolution of SARS-Cov2 Infections in Children With Inflammatory Bowel Disease: Results From Two International Databases.
Brenner EJ; Pigneur B; Focht G; Zhang X; Ungaro RC; Colombel JF; Turner D; Kappelman MD; Ruemmele FM
Clin Gastroenterol Hepatol; 2021 Feb; 19(2):394-396.e5. PubMed ID: 33059040
[TBL] [Abstract][Full Text] [Related]
19. Severe acute respiratory syndrome coronavirus 2 infection does not worsen the course of inflammatory bowel disease in the long term.
Neri B; D'Agostini G; Salvatori S; Mossa M; Bettin F; Mancone R; Marafini I; Lolli E; Calabrese E; Monteleone G; Biancone L
Eur J Gastroenterol Hepatol; 2023 Sep; 35(9):948-954. PubMed ID: 37505974
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of Epstein-Barr Virus in a population of patients with inflammatory bowel disease: a prospective cohort study.
Linton MS; Kroeker K; Fedorak D; Dieleman L; Fedorak RN
Aliment Pharmacol Ther; 2013 Nov; 38(10):1248-54. PubMed ID: 24053733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
